National and Kapodistrian University of Athens
Συσχέτιση των βιολογικών και κλινικών χαρακτηριστικών των πολυμορφισμών Asn/Ser, Asn/Asn, Ser/Ser του γονιδίου του υποδοχέα FSH καθώς και των πολυμορφισμών PvuII και RsaI των γονιδίων ESR1 και ESR2 των οιστρογονικών υποδοχέων ERα και ERβ στην εξωσωματική γονιμοποίηση
Abstract
dc:descriptionOvarian stimulation in Assisted Reproduction Techniques (ART) poses a question mark, especially during the first stimulation treatment. Several parameters like age, endocrine parameters (basal FSH, AMH, Inhibin B) and ultrasound parameters (antral follicular count) can be used to predict the ovarian reserve, with different sensitivity. Currently, no markers exist to guide clinicians in FSH starting dose selection, in ART protocols. This is based solely in clinician experience. The quantity of FSH used is arbitrary, which may lead either to low-dose and thus non-effective treatment, either to over-dose treatment with great risk for the appearance of ovarian hyperstimulation syndrome (OHSS). In order to be able to use reliable markers for the prediction of the ovarian response to controlled ovarian stimulation (COS), the research turned into the use of genetic markers and Pharmacogenetics. The ultimate goal of the field of Pharmacogenetics, combining the knowledge from pharmacology and genetics, is to optimize the administration of drugs, increase their efficacy and predict or even minimize their undesirable effects. In order to broaden the area of interest and to describe the important role of the whole genome on drug response, the term Pharmacogenomics has been issued. Pharmacogenomics covers the stydy of the genome and its products that are related to drug response (mRNA, proteins). By obtaining this knowledge, it will be possible to lead to the development of diagnostic tests to predict the efficacy and safety of a number of drugs, in order to achieve individualization of drug administration in patients. After 2000, when Perez-Mayorga presented evidence for the association of FSH receptor genotype with ovarian response to FSH in women undergoing controlled ovarian stimulation, the bibliography is rich in attempting to establish whether it exists an interaction between the genetic variability of FSH receptor and the exogenous use of FSH, the basal FSH levels, the ovarian response or the pregnancy rates. Concerning the oestrogen receptors, several studies have claimed that certain oestrogen receptor alpha gene (ESR1) polymorphisms may be involved in COS outcome and infertility. Moreover, there exist investigations on new polymorphisms concerning oestrogen receptor beta gene (ESR2). Heterogeneity of the results observed may be explained by the different ethnic populations involved and the design of the studies. Previous studies in humans concluded that a multigenic model including specific FSHR, ESR1 and ESR2 genotype patterns may partially explain the poor response to FSH. These polymorphisms seem to play a great part in determining the ovarian response in controlled ovarian stimulation during assisted reproduction techniques, considering women with normal ovarian function. These genetic alterations are a fine example when trying to relate genetic changes with the endocrine regulation of reproduction. The aim of our study is to analyse three different polymorphisms, PvuII (T/C) polymorphism in ESR1 gene, RsaI (G/A) polymorphism in ESR2 gene and Ser680Asn polymorphism in FSH receptor gene, in a Greek population and their involvement in ovarian stimulation outcome and pregnancy rates. A total of 109 normally ovulating female patients underwent IVF or ICSI. The genotyping for the three polymorphisms was performed with real-time polymerase chain reaction. Each locus was studied alone, and in combination with the others. The study focused in the associations of gene polymorphisms with COS and pregnancy outcome of IVF/ICSI, and in the associations of gene polymorphisms combinations with COS and pregnancy outcome of IVF/ICSI. Studying each locus alone, no significant results were drawn for ESR1 and ESR2 genes. Concerning the FSHR gene polymorphism, the women carrying the Asn/Asn variant presented higher total amount of gonadotrophins used (P=0.048) and tended to have higher number of stimulation days (P=0.057). Considering the ESR1 and FSHR gene polymorphisms in combination, the TC/SA combination presents the highest number of pregnancies in poor responders group (3/4 patients with pregnancy carried this genotype), in good responders group (4/12 patients with pregnancy carried this genotype) and in the total population (10/26 patients with pregnancy carried this genotype). All other genotype combinations presented incidence of pregnancy, except the CC/AA combination. The CC/AA genotype presents the worst profile of ovulation induction, confirming a poor responder profile: the total amount of gonadotrophins used was highest in CC/AA group (P<0.05). The peak E2, the number of follicles and of retrieved oocytes and the pregnancy rate were significantly lower (P<0.05). This genotype combination seems to be over-presented in the poor responders group in a statistically significant way (P=0.038). Women with CC/AA combination have 1.5- 2.4 times more risk to be poor responders in comparison with women that do not carry that combination. This study supports the hypothesis that an oligogenic model including the well studied ESR1 and FSHR genes is involved in the controlled ovarian stimulation outcome indicating that the CC/AA genotype presents the worst ovulation induction profile, while the TC/SA genotype presents the higher number of pregnancies in this population. This observation opens a new avenue for investigation of the genetic profile of patients that present many failures in previous IVF/ICSI attempts and support the choice of appropriate regimes for ovarian stimulation before enrolled in an IVF/ICSI procedure, depending on genetic markers The selection and combination of the appropriate genetic markers will lead in a better prediction of the ovarian response to stimulation and of pregnancy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Anagnostou, Elli
- Αναγνώστου, Έλλη
Subjects
dc:subject × 20- Πολυμορφισμοί
- Υποδοχέας FSH
- Οιστροτονικός υποδοχέας α
- Οιστροτονικός υποδοχέας β
- Υποβοηθούμενη αναπαραγωγή
- Φαρμακογενετική ανάλυση
- Πτωχή απαντήτρια
- Υπογονιμότητα
- Polymorphisms
- FSH receptor
- Oestrogen receptor-b beta
- Oesrogen receptor-a alpha
- Assisted reproduction
- Pharmacogenetics
- Poor respondens
- Infertility
- Ιατρική και Επιστήμες Υγείας
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27361